540 related articles for article (PubMed ID: 36569912)
21. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
Kuwahara M; Suzuki S; Takada K; Kusunoki S
J Neuroimmunol; 2011 Oct; 239(1-2):87-90. PubMed ID: 21914557
[TBL] [Abstract][Full Text] [Related]
22. [Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuropathy].
Kanbayashi T; Sonoo M
Brain Nerve; 2015 Nov; 67(11):1388-96. PubMed ID: 26560954
[TBL] [Abstract][Full Text] [Related]
23. Differentiation Between Guillain-Barré Syndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis-a Prospective Follow-up Study Using Ultrasound and Neurophysiological Measurements.
Grimm A; Oertl H; Auffenberg E; Schubert V; Ruschil C; Axer H; Winter N
Neurotherapeutics; 2019 Jul; 16(3):838-847. PubMed ID: 30756363
[TBL] [Abstract][Full Text] [Related]
24. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.
Ruts L; Drenthen J; Jacobs BC; van Doorn PA;
Neurology; 2010 May; 74(21):1680-6. PubMed ID: 20427754
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Plasma Exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Pham HP; Schwartz J
Presse Med; 2019 Nov; 48(11 Pt 2):338-346. PubMed ID: 31679897
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic effects of ginkgolides in Guillain-Barré syndrome and experimental autoimmune neuritis.
Li C; Liu S; Aerqin Q; Shen D; Wu X; Liu K
J Clin Neurosci; 2021 May; 87():44-49. PubMed ID: 33863532
[TBL] [Abstract][Full Text] [Related]
27. The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK cells in pathogenesis.
Blum S; Csurhes P; McCombe P
J Neuroimmunol; 2015 Aug; 285():53-6. PubMed ID: 26198918
[TBL] [Abstract][Full Text] [Related]
28. Attenuation of experimental autoimmune neuritis with locally administered lovastatin-encapsulating poly(lactic-co-glycolic) acid nanoparticles.
Langert KA; Goshu B; Stubbs EB
J Neurochem; 2017 Jan; 140(2):334-346. PubMed ID: 27861905
[TBL] [Abstract][Full Text] [Related]
29. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
Zhang HL; Zhang XM; Mao XJ; Deng H; Li HF; Press R; Fredrikson S; Zhu J
Acta Neurol Scand; 2012 Feb; 125(2):129-35. PubMed ID: 21434877
[TBL] [Abstract][Full Text] [Related]
30. Experimental neuritis induced by a mixture of neural antigens and influenza vaccines. A possible model for Guillain-Barré syndrome.
Hjorth RN; Bonde GM; Piner E; Hartzell RW; Rorke LB; Rubin BA
J Neuroimmunol; 1984 Feb; 6(1):1-8. PubMed ID: 6707195
[TBL] [Abstract][Full Text] [Related]
31. Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis.
Yan W; Nguyen T; Yuki N; Ji Q; Yiannikas C; Pollard JD; Mathey EK
J Neuroimmunol; 2014 Dec; 277(1-2):13-7. PubMed ID: 25262157
[TBL] [Abstract][Full Text] [Related]
32. Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets.
de Sèze J; Kremer L; Alves do Rego C; Taleb O; Lam D; Beiano W; Mensah-Nyagan G; Trifilieff E; Brun S
Rev Neurol (Paris); 2016 Dec; 172(12):767-769. PubMed ID: 27838091
[TBL] [Abstract][Full Text] [Related]
33. Are CSF or serum ganglioside antibodies related to peripheral nerve demyelination in neuroborreliosis, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy?
Weller M; Stevens A; Sommer N; Wiethölter H
Eur Arch Psychiatry Clin Neurosci; 1992; 242(2-3):122-6. PubMed ID: 1486101
[TBL] [Abstract][Full Text] [Related]
34. Roles of macrophage migration inhibitory factor in Guillain-Barré syndrome and experimental autoimmune neuritis: beneficial or harmful?
Shen D; Lang Y; Chu F; Wu X; Wang Y; Zheng X; Zhang HL; Zhu J; Liu K
Expert Opin Ther Targets; 2018 Jul; 22(7):567-577. PubMed ID: 29856236
[TBL] [Abstract][Full Text] [Related]
35. FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis.
Kremer L; Taleb O; Boehm N; Mensah-Nyagan AG; Trifilieff E; de Seze J; Brun S
J Neuroinflammation; 2019 Mar; 16(1):54. PubMed ID: 30825874
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of production of MIP-1alpha, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats.
Zou LP; Pelidou SH; Abbas N; Deretzi G; Mix E; Schaltzbeerg M; Winblad B; Zhu J
J Neuroimmunol; 1999 Aug; 98(2):168-75. PubMed ID: 10430050
[TBL] [Abstract][Full Text] [Related]
37. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy.
Inglis HR; Csurhes PA; McCombe PA
J Neurol Neurosurg Psychiatry; 2007 Apr; 78(4):419-22. PubMed ID: 17158557
[TBL] [Abstract][Full Text] [Related]
38. Treatment approaches for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Lindenbaum Y; Kissel JT; Mendell JR
Neurol Clin; 2001 Feb; 19(1):187-204. PubMed ID: 11471764
[TBL] [Abstract][Full Text] [Related]
39. What is new in 2015 in dysimmune neuropathies?
Kuntzer T
Rev Neurol (Paris); 2016 Dec; 172(12):779-784. PubMed ID: 27866728
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis of Guillain-Barré syndrome.
Hughes RA; Hadden RD; Gregson NA; Smith KJ
J Neuroimmunol; 1999 Dec; 100(1-2):74-97. PubMed ID: 10695718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
